FDA Nod Is Just the First Hurdle for Moderna’s Potential Blockbuster Flu Vax

FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax

Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.

First mRNA flu shot approved by FDA bodes well for improving drugs of the future – though a few hurdles remain before mRNA can move beyond vaccines

Li Li, UMass Chan Medical School Vaccines have been reliably and affordably protecting people from diseases worldwide for centuries. Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process. Traditionally, researchers had to tailor manufacturing processes and facilities for each vaccine candidate, and the scientific knowledge gained from one vaccine was often not directly transferable to another. But t…